Companies has developed a large number of biological macromolecular drugs through our own non-Ig antibody technology platform, the drugs had definite efficacy and safety, but targeting, medication adherence, bioavailability or process is difficult to adapt to the demands of clinical development , and we get biosimilars (biobetters) after reconstructing . First of all, the biosimilar varieties based on the platform technology can be product by cheaper E.Coli or yeast system for fermentation production, which get rid of expensive chemical synthesis or animal cell production technology, which fully adapted to the basic national conditions in our country: low purchasing power and the high quantity demanded . Secondly, the varieties based on the platform technology reduces the complexity of the design cost and effectiveness analysis, the success probability of biosimilars was increased significantly due to the known original product targets and pharmacology. Moreover, biosimilars can ensure the efficacy. Foreign experience shows that the failure primary reason in the market of biosimilar also tend to be due to unexpected side effects, rather than a lack of clinical efficacy. Finally, from the view of market, biosimilars are new products, differs from the imitation of biological drugs, has at least 12 years of market monopoly. The long exclusive market monopoly is significant to the expected profit. The improvement of product features will certainly attract more patients, and increase the product sales, the profit model driven not only by price.